FDA Approved: COSENTYX — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Cosentyx (secukinumab) submitted by Novartis Pharmaceuticals Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Non-radiographic Axial Spondyloarthritis
• Plaque Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

SUPPL AP for COSENTYX (SECUKINUMAB)